RESI JPM 2019 Innovation Challenge – Check Out the Winners

10 Jan

By Nono Hu, Director of Marketing, LSN

RESI JPM 2019 was the biggest Redefining Early Stage Investments event yet. In a highly competitive RESI Innovation Challenge we saw novel technologies represented from the therapeutics, medtech, diagnostics, and digital health verticals – we know it was tough for RESI attendees to choose how to allocate their 5 RESI “investment” tokens! We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Place: Novotalk

Novotalk provides an end-to-end digital therapy for people with speech disorders. It’s an online, on-demand (asynchronous), self-directed speech tele-therapy solution, which allows those with speech impairments to learn, practice, gain, and maintain comprehensible speech remotely, independently, and discretely. The user goes through therapy with a virtual clinician, together with algorithms that detect pre-defined speech patterns and provide feedback in real-time. The “real” clinician is a data-empowered supervisor to the process. We make therapy accessible, by removing the 2 main barriers to therapy; clinician availability and affordability. Novotalk’s first solution addresses stuttering, a condition which affects 370m people globally.

Jonathan Oron,VP R&D, Novotalk | Lilach Shvimer-Rothschild, Co-founder & COO, Novotalk | Dennis Ford, Founder & CEO, Life Science Nation | Zohar Beeri, CEO, Novotalk | Karen Deyo, Investor Research Analyst, Life Science Nation


Second Place: Heroic-Faith Medical Science

Established in June 2018, Heroic-Faith Medical Science Corp., LTD. is focused on the development of medical devices for the critical care medicine. The total annual spending on ICU care in North America in 2018 reaches $108 billion USD, being second only to cancer care which totals $158 billion USD, making it a key market that is marked by costly spending, as well as one that is open to new ideas. We hope to combine Taiwan’s advanced medical expertise with its cutting-edge electronics capabilities to develop break-through products, so that we can realize the ideal of our CEO, “Saving lives through innovation”, in the global market.

Fushun Hsu, CEO, Heroic-Faith Medical Science | Yuan-Ren Cheng, COO, Heroic-Faith Medical Science | Dennis Ford, Founder & CEO, Life Science Nation | Lucy Parkinson, VP of Investor Research, Life Science Nation


Third Place: MedTrace A/S

MedTrace is a development-stage company innovating PET diagnostic imaging with an end-to-end solution for a best-in-class blood flow tracer geared for better outcomes, attractive economics and high-patient throughput.

• PET scans are the most sensitive and precise diagnostic tools available in medical imaging.

• There is a significant unmet need in cardiology for improved diagnostic images to guide invasive and non-invasive treatment.

• One of the fundamental challenges in PET cardiology diagnostics is the global scarcity of tracers.

• MedTrace has developed a solution that enables the practical incorporation of the gold-standard radiotracer, 15O-water, for PET cardiology imaging.

• MedTrace’s beachhead will be in the inefficiently-served Myocardial Ischemia market.

Rune Wiik Kristensen, COO, MedTrace | Martin Stenfeldt, CEO, MedTrace | Dennis Ford, Founder & CEO, Life Science Nation | Lucy Parkinson, VP of Investor Research, Life Science Nation

Hot Investor Mandate: Corporate Venture Firm Seeks to Invest Broadly Across Life Sciences, with Strongest Interests in Novel Drug Delivery Systems

3 Jan

A corporate venture arm of a leading electronic solutions provider looks at life sciences as one of their main focus areas. The firm focuses on strategic investments in which the corporate could bring significant value, and those that supplement the corporate’s business areas. The firm invests up to $10M over the lifetime of the company, usually between Series A to C rounds but looks even earlier for life science-related opportunities. The firm usually invests around $5M initially and reserves capital for follow-on investment. The corporate has a global footprint, with manufacturing plants throughout USA, China, and Thailand. The firm is open to global opportunities including those in rapidly growing markets like China and India. The firm is expecting to close 3 new investments in Q1 2019.

Within the early-stage life sciences ecosystem, the firm is most interested in novel drug delivery systems with target indications including oncology, cardiovascular, diabetes, and COPD. The firm also has a strong interest in technologies with a connected health component. The firm is open to all early-stage opportunities that are relevant to the firm’s focus areas, but those who do not yet have a working prototype would be considered too early for the firm. The firm is open to all classes of devices including 510k and PMA.

The firm can act as either the lead or co-investor. The firm would prefer to see companies that already have some sort of commercial engagement established. The firm aims to bring strategic value into their portfolio companies, such as working on product design and development. If the company already has such manufacturing partnership established, it is unlikely for the firm to invest in the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Global Investment Firm Invests Up to $25M in USA-Based Life Science Companies with High Growth Potential

3 Jan

A global investment firm founded in 2005 has about $300 AUM and invests in a wide variety of sectors, with healthcare being one of the major areas of interest. The firm can invest anywhere from $0.25 – 25M, depending on the company’s stage of development. Currently, the firm is primarily investing in USA-based opportunities.

The firm is opportunistic in terms of technology and indication and will consider all types of technologies with high growth potential, in therapeutics, medical devices, diagnostics, and digital health sectors. The firm is the largest stakeholder in a late-clinical-stage therapeutics company, but the firm is certainly open to pre-clinical therapeutics companies as well.

The firm no specific management team requirements. The firm often leads investment rounds, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: